These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33376084)

  • 41. Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries.
    Hartmann B; Lanzinger S; van Mark G; Wosch FJ; Durmaz M; Plaumann M; Sziegoleit S; Seufert J; Holl RW; Bramlage P;
    Acta Diabetol; 2020 Feb; 57(2):229-236. PubMed ID: 31471633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus.
    Asche CV; Bode B; Busk AK; Nair SR
    Diabetes Obes Metab; 2012 Jan; 14(1):47-57. PubMed ID: 21834876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes.
    Boye KS; Mody R; Lage MJ; Malik RE
    Clin Ther; 2020 Sep; 42(9):1812-1817.e2. PubMed ID: 32741645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs.
    Levin P; Zhou S; Durden E; Farr AM; Gill J; Wei W
    Clin Ther; 2016 Jan; 38(1):110-21. PubMed ID: 26681210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
    Pan C; Han P; Ji L; Ji Q; Lu J; Lin J; Liu J; Su B; Shi J; Wang P
    J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.
    Carls GS; Tuttle E; Tan RD; Huynh J; Yee J; Edelman SV; Polonsky WH
    Diabetes Care; 2017 Nov; 40(11):1469-1478. PubMed ID: 28801475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1149-1167. PubMed ID: 29675798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.
    Rosenstock J; Ampudia-Blasco FJ; Lubwama R; Peng XV; Boss A; Shi L; Fonseca V
    Diabetes Obes Metab; 2020 Dec; 22(12):2295-2304. PubMed ID: 32729183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin.
    Hopton OM; Waterbury NV; Egge JA; Lund BC
    Pharmacotherapy; 2022 Jan; 42(1):45-52. PubMed ID: 34807465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.
    Göke R; Bader G; Dworak M
    Diabetes Ther; 2014 Jun; 5(1):183-91. PubMed ID: 24643724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater.
    Tran V; Tran H; Demirel S; Thompson-Moore N
    J Pharm Pract; 2023 Oct; 36(5):1125-1133. PubMed ID: 35427194
    [No Abstract]   [Full Text] [Related]  

  • 55. Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting.
    Canivell S; Mata-Cases M; Real J; Franch-Nadal J; Vlacho B; Khunti K; Gratacòs M; Mauricio D
    Diabetes Obes Metab; 2019 Jun; 21(6):1373-1380. PubMed ID: 30756446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET).
    Evans M; Chandramouli AS; Faurby M; Matthiessen KS; Mogensen PB; Verma S
    Diabetes Obes Metab; 2022 Jul; 24(7):1300-1309. PubMed ID: 35504854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes.
    Gavigan C; Donner T
    J Diabetes Res; 2023; 2023():9972132. PubMed ID: 37589043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of antidiabetic therapies to glycemic control and to body weight in type 2 diabetes: a German multicenter analysis on 9294 patients.
    Schütt M; Kern W; Zimmermann A; Busch P; Kerner W; Voll A; Wagner C; Kann PH; Dapp A; Holl RW; ;
    Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):490-5. PubMed ID: 20200811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
    Chou HW; Cheng KP; Lin AC; Hung HC; Lin CH; Wang CC; Wu HT; Ou HY
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: A retrospective UK cohort study.
    Jude EB; Trescoli C; Emral R; Ali A; Lubwama R; Palmer K; Shaunik A; Nanda N; Raskin P; Gomez-Peralta F
    Diabetes Obes Metab; 2021 Apr; 23(4):929-937. PubMed ID: 33319424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.